Skip to main content
SpringerLink
Log in

Diabetic Eye Disease

  • Chapter
  • First Online:
Diabetes and Kidney Disease

  • 1931 Accesses

Abstract

Diabetes mellitus is a universal disease that has been associated with a significant increase in incidence among all regions of the world and in all races, ages, and sexes over the last several decades. If the same explosion of the disease continues, it is estimated that there will be over 350 million diabetics worldwide in 2030. Over 30 % of diabetic patients have some form of diabetic eye disease, mostly diabetic retinopathy (DR). Diabetic retinopathy is the leading cause of preventable blindness among individuals of working age, and a major cause of vision loss in the elderly population. Visual loss develops secondary to complications of DR such as diabetic macular edema and ischemia, vitreous hemorrhage, and retinal detachment. Glaucoma, another common cause of blindness, also occurs more often in diabetics and carries a worse prognosis compared to nondiabetics.

Although the pathogenesis is not completely understood, diabetes is a widespread microangiopathy associated with pericyte-deficient small vessels and “degenerating” capillaries that gradually interfere with the circulation everywhere in the body. For example, the retinal and glomerular vessels are both affected with microangiopathy in patients with type 1 and type 2 diabetes mellitus and present similar morphologic alterations. In DR, capillary degeneration and occlusion initially happen in isolated channels without clinical significance. Later however, more capillaries become occluded and the circulation is disrupted and the retina eventually becomes ischemic. In addition to pathogenic and epidemiologic aspects of the disease this chapter covers the up-to-date methods to diagnose, monitor, and treat DR.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ho AC, Scott IU, Kim SJ, et al. Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology. Ophthalmology. 2012;119: 2179–88.

    Article  PubMed  Google Scholar 

  2. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124–36.

    Article  PubMed  Google Scholar 

  3. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115:1859–68.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Klein R, Knudtson M, Lee K, Gangnon R, Klein B. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009;116:497–503.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Klein R, Zinman B, Gardiner R, et al. The relationship of diabetic retinopathy to preclinical diabetic glomerulopathy lesions in type 1 diabetic patients: the Renin-Angiotensin System Study. Diabetes. 2005;54:527–33.

    Article  CAS  PubMed  Google Scholar 

  6. Klein R, Knudtson MD, Klein BE, et al. The relationship of retinal vessel diameter to changes in diabetic nephropathy structural variables in patients with type 1 diabetes. Diabetologia. 2010;53:1638–46.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Schwartz MM, Lewis EJ, Leonard-Martin T, Lewis JB, Batlle D. Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy. The Collaborative Study Group. Nephrol Dial Transplant. 1998;13:2547–52.

    Article  CAS  PubMed  Google Scholar 

  8. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res. 2007;2007:95103.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Kern T, Mohr S. Nonproliferative stages of diabetic retinopathy: animal models and pathogenesis. In: Joussen AM, Gardner GM, Kirchhof B, Ryan SJ, editors. Retinal vascular disease. New York: Springer; 2007. p. 303–11.

    Google Scholar 

  10. Hammes HP, Federoff HJ, Brownlee M. Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes. Mol Med. 1995;1:527–34.

    CAS  PubMed Central  PubMed  Google Scholar 

  11. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest. 1998;102:783–91.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329:304–9.

    Article  CAS  PubMed  Google Scholar 

  13. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes. 1996;45:1289–98.

    Google Scholar 

  14. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes. 1995;44:968–83.

    Google Scholar 

  15. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. Arch Ophthalmol. 1995;113:36–51.

    Google Scholar 

  16. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977–86.

    Google Scholar 

  17. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563–9.

    Google Scholar 

  18. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:854–65.

    Google Scholar 

  19. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837–53.

    Google Scholar 

  20. Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233–44.

    Article  PubMed  Google Scholar 

  21. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703–13.

    Google Scholar 

  22. Mitchell P, Wong TY. DIRECT new treatments for diabetic retinopathy. Lancet. 2008;372:1361–3.

    Article  PubMed  Google Scholar 

  23. Chaturvedi N, Porta M, Klein R, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet. 2008;372:1394–402.

    Article  CAS  PubMed  Google Scholar 

  24. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361: 40–51.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Lyons TJ, Jenkins AJ, Zheng D, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci. 2004;45:910–8.

    Article  PubMed  Google Scholar 

  26. Raman R, Rani PK, Kulothungan V, Rachepalle SR, Kumaramanickavel G, Sharma T. Influence of serum lipids on clinically significant versus nonclinically significant macular edema: SN-DREAMS report number 13. Ophthalmology. 2010;117:766–72.

    Article  PubMed  Google Scholar 

  27. Benarous R, Sasongko MB, Qureshi S, et al. Differential association of serum lipids with diabetic retinopathy and diabetic macular edema. Invest Ophthalmol Vis Sci. 2011;52:7464–9.

    Article  CAS  PubMed  Google Scholar 

  28. The Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the Diabetes Control and Complications Trial. Diabetes Care 2000;23:1084–91.

    Google Scholar 

  29. Rasmussen KL, Laugesen CS, Ringholm L, Vestgaard M, Damm P, Mathiesen ER. Progression of diabetic retinopathy during pregnancy in women with type 2 diabetes. Diabetologia. 2010;53:1076–83.

    Article  CAS  PubMed  Google Scholar 

  30. Vestgaard M, Ringholm L, Laugesen CS, Rasmussen KL, Damm P, Mathiesen ER. Pregnancy-induced sight-threatening diabetic retinopathy in women with Type 1 diabetes. Diabet Med. 2010;27:431–5.

    Article  CAS  PubMed  Google Scholar 

  31. Romero-Aroca P, Baget-Bernaldiz M, Reyes-Torres J, et al. Relationship between diabetic retinopathy, microalbuminuria and overt nephropathy, and twenty-year incidence follow-up of a sample of type 1 diabetic patients. J Diabetes Complications. 2012;26:506–12.

    Article  PubMed  Google Scholar 

  32. Karlberg C, Falk C, Green A, Sjolie AK, Grauslund J. Proliferative retinopathy predicts nephropathy: a 25-year follow-up study of type 1 diabetic patients. Acta Diabetol. 2012;49:263–8.

    Article  PubMed  Google Scholar 

  33. Berman DH, Friedman EA. Partial absorption of hard exudates in patients with diabetic end-stage renal disease and severe anemia after treatment with erythropoietin. Retina. 1994;14:1–5.

    CAS  PubMed  Google Scholar 

  34. Qiao Q, Keinanen-Kiukaanniemi S, Laara E. The relationship between hemoglobin levels and diabetic retinopathy. J Clin Epidemiol. 1997;50:153–8.

    Article  CAS  PubMed  Google Scholar 

  35. Shorb SR. Anemia and diabetic retinopathy. Am J Ophthalmol. 1985;100:434–6.

    CAS  PubMed  Google Scholar 

  36. West SD, Groves DC, Lipinski HJ, et al. The prevalence of retinopathy in men with Type 2 diabetes and obstructive sleep apnoea. Diabet Med. 2010;27:423–30.

    Article  CAS  PubMed  Google Scholar 

  37. Nguyen TT, Alibrahim E, Islam FM, et al. Inflammatory, hemostatic, and other novel biomarkers for diabetic retinopathy: the multi-ethnic study of atherosclerosis. Diabetes Care. 2009;32:1704–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Sobrin L, Green T, Sim X, et al. Candidate gene association study for diabetic retinopathy in persons with type 2 diabetes: the Candidate gene Association Resource (CARe). Invest Ophthalmol Vis Sci. 2011;52:7593–602.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. Abhary S, Hewitt AW, Burdon KP, Craig JE. A systematic meta-analysis of genetic association studies for diabetic retinopathy. Diabetes. 2009;58:2137–47.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  40. Arar NH, Freedman BI, Adler SG, et al. Heritability of the severity of diabetic retinopathy: the FIND-Eye study. Invest Ophthalmol Vis Sci. 2008;49:3839–45.

    Article  PubMed Central  PubMed  Google Scholar 

  41. Liew G, Klein R, Wong TY. The role of genetics in susceptibility to diabetic retinopathy. Int Ophthalmol Clin. 2009;49:35–52.

    Article  PubMed Central  PubMed  Google Scholar 

  42. Cruickshanks KJ, Ritter LL, Klein R, Moss SE. The association of microalbuminuria with diabetic retinopathy. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology. 1993;100:862–7.

    Article  CAS  PubMed  Google Scholar 

  43. Nwanyanwu KH, Talwar N, Gardner TW, Wrobel JS, Herman WH, Stein JD. Predicting development of proliferative diabetic retinopathy. Diabetes Care. 2013;36(6):1562–8.

    Article  Google Scholar 

  44. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol. 1985;103:1796–806.

    Google Scholar 

  45. Frank RN, Hoffman WH, Podgor MJ, et al. Retinopathy in juvenile-onset type I diabetes of short duration. Diabetes. 1982;31:874–82.

    Article  CAS  PubMed  Google Scholar 

  46. Frank RN, Hoffman WH, Podgor MJ, et al. Retinopathy in juvenile-onset diabetes of short duration. Ophthalmology. 1980;87:1–9.

    Article  CAS  PubMed  Google Scholar 

  47. American Academy of Ophthalmology. Preferred practice pattern. Diabetic retinopathy. San Francisco: AAO; 2008.

    Google Scholar 

  48. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet. 1998;351:28–31.

    Article  CAS  PubMed  Google Scholar 

  49. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370:1687–97.

    Article  CAS  PubMed  Google Scholar 

  50. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology 1978;85:82–106.

    Google Scholar 

  51. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010; 117:1064–77.e35.

    Article  PubMed Central  PubMed  Google Scholar 

  52. Googe J, Brucker AJ, Bressler NM, et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina. 2011;31:1009–27.

    Article  CAS  PubMed  Google Scholar 

  53. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117:1078–86.e2.

    Article  PubMed  Google Scholar 

  54. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615–25.

    Article  PubMed  Google Scholar 

  55. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789–801.

    Article  PubMed  Google Scholar 

  56. Beck RW, Edwards AR, Aiello LP, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009;127:245–51.

    Article  PubMed  Google Scholar 

  57. Gillies MC, McAllister IL, Zhu M, et al. Pretreatment with intravitreal triamcinolone before laser for diabetic macular edema: 6-month results of a randomized, placebo-controlled trial. Invest Ophthalmol Vis Sci. 2010;51:2322–8.

    Article  PubMed  Google Scholar 

  58. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006;113:1533–8.

    Article  PubMed  Google Scholar 

  59. Pearson PA, Comstock TL, Ip M, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology. 2011;118:1580–7.

    Article  PubMed  Google Scholar 

  60. Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119:2125–32.

    Article  PubMed  Google Scholar 

  61. Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118:626–35.e2.

    Article  PubMed  Google Scholar 

  62. Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010;128:289–96.

    Article  CAS  PubMed  Google Scholar 

  63. Inoue K, Kato S, Ohara C, Numaga J, Amano S, Oshika T. Ocular and systemic factors relevant to diabetic keratoepitheliopathy. Cornea. 2001;20:798–801.

    Article  CAS  PubMed  Google Scholar 

  64. Dogru M, Katakami C, Inoue M. Tear function and ocular surface changes in noninsulin-dependent diabetes mellitus. Ophthalmology. 2001;108:586–92.

    Article  CAS  PubMed  Google Scholar 

  65. Nepp J, Abela C, Polzer I, et al. Is there a correlation between the severity of diabetic retinopathy and keratoconjunctivitis sicca? Cornea. 2000;19:487–91.

    Article  CAS  PubMed  Google Scholar 

  66. Kallinikos P, Berhanu M, O’Donnell C, et al. Corneal nerve tortuosity in diabetic patients with neuropathy. Invest Ophthalmol Vis Sci. 2004;45:418–22.

    Article  PubMed  Google Scholar 

  67. Midena E, Brugin E, Ghirlando A, et al. Corneal diabetic neuropathy: a confocal microscopy study. J Refract Surg. 2006;22: S1047–52.

    PubMed  Google Scholar 

  68. Nitoda E, Kallinikos P, Pallikaris A, et al. Correlation of diabetic retinopathy and corneal neuropathy using confocal microscopy. Curr Eye Res. 2012;37:898–906.

    Article  CAS  PubMed  Google Scholar 

  69. Vaphiades MS. The disk edema dilemma. Surv Ophthalmol. 2002;47(2):183.

    Article  PubMed  Google Scholar 

  70. Pavan PR, Aiello LM, Wafai MZ, et al. Optic disc edema in juvenile-onset diabetes. Arch Ophthalmol. 1980;98(12):2193–7.

    Article  CAS  PubMed  Google Scholar 

  71. Bayraktar Z, Alacali N. Bayraktar: diabetic papillopathy in type II diabetic patients. Retina. 2002;22(6):752.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Stony Brook University, Stony Brook, NY, USA

    Azin Abazari M.D.

  2. King Khaled Eye Specialist Hospital, 7191, Riyadh, 11462, Saudi Arabia

    Nicola G. Ghazi M.D.

  3. University of Virginia, Charlottesville, VA, USA

    Nicola G. Ghazi M.D.

  4. Department of Ophthalmology, University of Virginia, 300 Jefferson Park Avenue, OMS 2783, Charlottesville, VA, 22908, USA

    Zeynel A. Karcioglu M.D.

Authors
  1. Azin Abazari M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicola G. Ghazi M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zeynel A. Karcioglu M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Azin Abazari M.D. , Nicola G. Ghazi M.D. or Zeynel A. Karcioglu M.D. .

Editor information

Editors and Affiliations

  1. University of Illinois, Chicago, Illinois, USA

    Edgar V. Lerma

  2. Nephrology Section, Tulane University Medical School, New Orleans, Louisiana, USA

    Vecihi Batuman

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Abazari, A., Ghazi, N.G., Karcioglu, Z.A. (2014). Diabetic Eye Disease. In: Lerma, E., Batuman, V. (eds) Diabetes and Kidney Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0793-9_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-0793-9_13

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-0792-2

  • Online ISBN: 978-1-4939-0793-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation